| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Letter
- Language: English
- [Bone Marrow Transplant] 2024 Apr; Vol. 59 (4), pp. 564-565. <i>Date of Electronic Publication: </i>2024 Jan 23.
- MeSH Terms: Cytomegalovirus Infections* / drug therapy ; Hematopoietic Stem Cell Transplantation* / adverse effects ; Acetates* ; Quinazolines* ; Humans ; Incidence ; Cytomegalovirus ; Antiviral Agents / therapeutic use
- References: Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38. (PMID: 10.1182/blood-2015-11-679639268843744874224) ; Eberhardt KA, Jung V, Knops E, Heger E, Wirtz M, Steger G, et al. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transpl. 2023;58:639–46. (PMID: 10.1038/s41409-023-01944-2) ; Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2020;34:e00043–19. (PMID: 10.1128/CMR.00043-19331157227920732) ; Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44. (PMID: 10.1056/NEJMoa170664029211658) ; Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34–43. (PMID: 10.1182/blood.2020009396336572258493975) ; Sepassi A, Saunders IM, Bounthavong M, Taplitz RA, Logan C, Watanabe JH. Effectiveness of Letermovir for Cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: a global systematic review. J Am Pharm Assoc 2023. 2003;63:1138–49. (PMID: 10.1016/j.japh.2023.05.015) ; Sourisseau M, Faure E, Behal H, Chauvet P, Srour M, Capes A, et al. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Adv. 2023;7:856–65. (PMID: 10.1182/bloodadvances.202200866736350752) ; Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, et al. Letermovir Discontinuation at Day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transpl Cell Ther. 2022;28:510.e1–e9. (PMID: 10.1016/j.jtct.2022.05.020) ; Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with Letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2023;10:ofac687. (PMID: 10.1093/ofid/ofac68736726548)
- Substance Nomenclature: 1H09Y5WO1F (letermovir) ; 0 (Antiviral Agents) ; 0 (Acetates) ; 0 (Quinazolines)
- Entry Date(s): Date Created: 20240123 Date Completed: 20240408 Latest Revision: 20240408
- Update Code: 20240408
|
